LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multiplex PCR Developed for Neglected Infectious Diseases

By LabMedica International staff writers
Posted on 01 Aug 2019
Print article
Image: The Applied Biosystems Veriti HID 96-Well Thermal Cycler (Photo courtesy of Thermo Fisher Scientific).
Image: The Applied Biosystems Veriti HID 96-Well Thermal Cycler (Photo courtesy of Thermo Fisher Scientific).
Scrub typhus, murine typhus, and leptospirosis are diagnosed as acute undifferentiated febrile illness. Diagnostic tests for these diseases depend on antibody detection. However, antibody detection is still limited by its tendency to return negative results during the early phase of these diseases.

Early clinical manifestations of scrub typhus, murine typhus, and leptospirosis, such as high fever, headache, muscular pain, and anorexia, are non-specific and usually diagnosed as acute undifferentiated febrile illness. These clinical manifestations range from mild, severe, to possibly fatal.

Scientists at the Chulalongkorn University (Bangkok, Thailand) and their colleagues used 83 EDTA blood samples taken from patients presented with acute undifferentiated febrile illness at various institutions. Patients included were over 18 years old, having acute fever (38 °C or higher), exhibiting non-specific symptoms, (headache, muscular pain, anorexia, and rash for 3–5 days), and tested negative for both influenza and dengue antigens.

The team developed a multiplex polymerase chain reaction PCR to combine three primer pairs that target specific genes encoding 56-kDa TSA of Orientia tsutsugamushi, 17-kDa antigen of Rickettsia typhi, and LipL32 of Leptospira interrogans and evaluate its performance in comparison to the standard serological tests. Multiplex PCR amplification was performed on a Thermal Cycler. Specificity of the multiplex PCR was tested with unrelated pathogens.

Multiplex PCR results were positive in 39 samples (47%), consisting of 22 samples of scrub typhus (26.5%), 11 samples of leptospirosis (13.25%), five samples of murine typhus (6.02%), and one sample of co-infection between scrub typhus and leptospirosis (1.2%). Twenty samples were detected by both serological methods and multiplex PCR. Nineteen samples were detected only by multiplex PCR but tested negative by standard serological methods. The diagnostic sensitivity and specificity of multiplex PCR were 100% and 70%, respectively, when serological methods were used as gold standard. Positive predictive value and negative predictive value of this assay were 51% and 100%, respectively.

The authors concluded that they had developed a novel multiplex PCR assay for identifying causative agents of scrub typhus, murine typhus, and leptospirosis in blood samples. This method is a rapid, sensitive, and specific diagnostic test. The multiplex PCR assay will become useful for the development of better health care and treatment of patients presented with acute undifferentiated febrile illness, particularly in endemic areas of these diseases. The study was published on July 8, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Chulalongkorn University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.